954 related articles for article (PubMed ID: 15368155)
21. Functional iron deficiency in hemodialysis patients with high ferritin.
Kopelman RC; Smith L; Peoples L; Biesecker R; Rizkala AR
Hemodial Int; 2007 Apr; 11(2):238-46. PubMed ID: 17403177
[TBL] [Abstract][Full Text] [Related]
22. Clinical review of the newer intravenous iron therapy options.
Edwards JH
Nephrol Nurs J; 2003 Feb; 30(1):70-3. PubMed ID: 12674953
[TBL] [Abstract][Full Text] [Related]
23. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
[TBL] [Abstract][Full Text] [Related]
24. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
25. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
26. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients.
Besarab A; Amin N; Ahsan M; Vogel SE; Zazuwa G; Frinak S; Zazra JJ; Anandan JV; Gupta A
J Am Soc Nephrol; 2000 Mar; 11(3):530-538. PubMed ID: 10703677
[TBL] [Abstract][Full Text] [Related]
27. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
[TBL] [Abstract][Full Text] [Related]
28. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
[TBL] [Abstract][Full Text] [Related]
29. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
31. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
Fishbane S; Frei GL; Maesaka J
Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
[TBL] [Abstract][Full Text] [Related]
32. Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis.
Kato A; Hamada M; Suzuki T; Maruyama T; Maruyama Y; Hishida A
Nephron; 2001 Sep; 89(1):110-2. PubMed ID: 11528242
[TBL] [Abstract][Full Text] [Related]
33. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron.
Gotloib L; Silverberg D; Fudin R; Shostak A
J Nephrol; 2006; 19(2):161-7. PubMed ID: 16736414
[TBL] [Abstract][Full Text] [Related]
34. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
Trenkle JA
Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
[TBL] [Abstract][Full Text] [Related]
35. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
36. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
37. Unanticipated favorable effects of correcting iron deficiency in chronic hemodialysis patients.
Pollak VE; Lorch JA; Means RT
J Investig Med; 2001 Mar; 49(2):173-83. PubMed ID: 11288758
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
39. Anemia of chronic renal failure: new treatment alternative.
Seiler S
CANNT J; 2000; 10(3):35-9, 43-8; quiz 40-2, 49-51. PubMed ID: 11799582
[TBL] [Abstract][Full Text] [Related]
40. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV
Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
